This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Now the Right Time to Hold on to Charles River Stock?
by Zacks Equity Research
CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors.
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRL Gears Up for Q4 Earnings: Here's What You Need to Know
by Zacks Equity Research
Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises
by Zacks Equity Research
CRL introduces Apollo for CRADL, integrating the technology stack across its robust portfolio.
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line?
by Zacks Equity Research
Charles River and Akron Bio collaborate to boost operations by integrating CGMP materials into the Cell Therapy Platform.
Should You Retain Charles River Stock in Your Portfolio Now?
by Zacks Equity Research
CRL's solid prospects in the RMS segment and solid financial stability create a favorable outlook for investors.
Why Is Charles River (CRL) Down 8.9% Since Last Earnings Report?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRL Stock to Gain From the Global Biotech Incubator Program Launch
by Zacks Equity Research
Charles River's new initiative specifically caters to early-stage biotechnology developers.
Is it the Right Time to Hold Charles River Stock in Your Portfolio?
by Zacks Equity Research
Investors are optimistic about CRL stock due to its strong RMS prospects and inorganic growth efforts.
Charles River (CRL) International Revenue in Focus: Trends and Expectations
by Zacks Equity Research
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Charles River's Q3 Earnings, Revenues Beat Estimates, Margins Fall
by Zacks Equity Research
CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is more than offset by lower revenues in the DSA segment.
Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Charles River Laboratories (CRL) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 6.58% and 3.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Gear Up for Charles River (CRL) Q3 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Charles River (CRL) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Pediatrix Medical Group (MD) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 18.92% and 2.21%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Charles River (CRL) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CRL Gears Up for Q3 Earnings: Here's What You Need to Know
by Zacks Equity Research
Growth across all businesses within the Manufacturing segment is likely to have contributed to Charles River's Q3 revenues, offset by lower biopharmaceutical demand.
CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch
by Zacks Equity Research
Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro.
CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica
by Zacks Equity Research
Charles River and Lundbeck sign an agreement to use Logica to advance the discovery of novel neurological drugs.
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA
by Zacks Equity Research
Charles River collaborates with CEBINA as part of the DanubeNeuro program to advance innovation in neurodegeneration.
CRL Stock May Benefit From New Neuroscience Research Collaboration
by Zacks Equity Research
Charles River's new alliance with Insightec to advance therapeutic development using focused ultrasound in neuroscience.
Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Charles River (CRL) International Revenue Trends Deserve Your Attention
by Zacks Equity Research
Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down
by Zacks Equity Research
Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.